
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="152543648AF2E3D305436400265863EE.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="scirep">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370928/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Scientific Reports">
<meta name="citation_title" content="Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration">
<meta name="citation_author" content="Masaaki Saito">
<meta name="citation_author_institution" content="Department of Regional Vision Reconstruction, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295 Japan">
<meta name="citation_author_institution" content="Iwaki City Medical Center, Iwaki, Japan">
<meta name="citation_author" content="Kimihiro Imaizumi">
<meta name="citation_author_institution" content="Iwaki City Medical Center, Iwaki, Japan">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="15">
<meta name="citation_firstpage" content="30699">
<meta name="citation_doi" content="10.1038/s41598-025-15194-3">
<meta name="citation_pmid" content="40841412">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370928/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370928/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370928/pdf/41598_2025_Article_15194.pdf">
<meta name="description" content="We evaluated the efficacy of switching to intravitreal injection of faricimab (IVF) in patients with aflibercept-refractory neovascular age-related macular degeneration (nAMD) over 2 years of follow-up. We retrospectively reviewed 47 consecutive ...">
<meta name="og:title" content="Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="We evaluated the efficacy of switching to intravitreal injection of faricimab (IVF) in patients with aflibercept-refractory neovascular age-related macular degeneration (nAMD) over 2 years of follow-up. We retrospectively reviewed 47 consecutive ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370928/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12370928">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41598-025-15194-3"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41598_2025_Article_15194.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12370928%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12370928/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12370928/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370928/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-scirep.jpg" alt="Scientific Reports logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Scientific Reports" title="Link to Scientific Reports" shape="default" href="http://www.nature.com/srep" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Sci Rep</button></div>. 2025 Aug 21;15:30699. doi: <a href="https://doi.org/10.1038/s41598-025-15194-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41598-025-15194-3</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sci%20Rep%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sci%20Rep%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Saito%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Masaaki Saito</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Masaaki Saito</span></h3>
<div class="p">
<sup>1</sup>Department of Regional Vision Reconstruction, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295 Japan </div>
<div class="p">
<sup>2</sup>Iwaki City Medical Center, Iwaki, Japan </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Saito%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Masaaki Saito</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Imaizumi%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Kimihiro Imaizumi</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Kimihiro Imaizumi</span></h3>
<div class="p">
<sup>2</sup>Iwaki City Medical Center, Iwaki, Japan </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Imaizumi%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kimihiro Imaizumi</span></a>
</div>
</div>
<sup>2</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Regional Vision Reconstruction, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295 Japan </div>
<div id="Aff2">
<sup>2</sup>Iwaki City Medical Center, Iwaki, Japan </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Apr 1; Accepted 2025 Aug 6; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12370928  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40841412/" class="usa-link">40841412</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par7">We evaluated the efficacy of switching to intravitreal injection of faricimab (IVF) in patients with aflibercept-refractory neovascular age-related macular degeneration (nAMD) over 2 years of follow-up. We retrospectively reviewed 47 consecutive eyes of 45 Japanese patients with nAMD who switched from aflibercept to faricimab. Thirty-one eyes of 30 Japanese patients were included in this study. The mean visual acuity (BCVA) at month 24 was stable relative to the baseline. The mean central retinal thickness and subfoveal choroidal thinning significantly decreased at 24 months (<em>P</em> &lt; 0.0001, <em>P</em> &lt; 0.0001, respectively). At 24 months, 22 eyes (70.0%) achieved a dry macula and had improved VA levels with an improvement of 0.80 lines, which was significantly different from the remaining 9 eyes (<em>P</em> &lt; 0.01). The mean interval of IVF was 11.8 weeks, which was significantly longer than that of aflibercept (10.0 weeks) at baseline (<em>p</em> = 0.014). Progression of macular atrophy or newly developing macular atrophy was seen in 3 eyes (9.7%), showing decline of 1.0 line, no other complications were seen. These results indicate that switching to IVF stabilized VA, significantly improved the anatomical changes and the achievement of a dry macula was significantly associated with the visual outcome, in patients with aflibercept-refractory nAMD over a 24-month period.</p>
<section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Neovascular age-related macular degeneration , Macular neovascularization, Faricimab, Aflibercept, Refractory, Optical coherence tomography angiography</p></section><section id="kwd-group2" class="kwd-group"><p><strong>Subject terms:</strong> Macular degeneration, Retinal diseases</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par8">Macular neovascularization (MNV), which has been used as a term for choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD), causes significant visual loss<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>–<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a></sup>. nAMD can be divided into types 1 and 2, mixed types 1 and 2, 3 and polypoidal choroidal vasculopathy (PCV), and it is well-known that the prevalence of nAMD differs between Caucasians and Asians<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>–<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a></sup>.</p>
<p id="Par9">Intravitreal injection of anti-vascular endothelial growth factor (VEGF) using bevacizumab (off-label), ranibizumab, aflibercept (IVA 2 mg), brolucizumab, and new anti-VEGF drugs (faricimab or aflibercept [IVA 8 mg]) in patients with nAMD is considered to be a major first-choice treatment that is both reasonable and useful based on evidence of the relationship between VEGF and MNV complexes in vitro and in clinical trials<sup><a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>–<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a></sup>. Anti-VEGF drugs tend to elicit different responses based on MNV subtypes in clinical settings. Furthermore, a long-term follow-up study for nAMD treated with ranibizumab demonstrated that the mean best-corrected VA (BCVA) declined to a mean of 8.6 letters due to the development of macular atrophy and persistence of active exudative disease at 7 years<sup><a href="#CR20" class="usa-link" aria-describedby="CR20">20</a></sup>. It is well known that brolucizumab has superior effectiveness to aflibercept in reducing exudation in patients with nAMD; however, it is associated with a risk of intraocular inflammation (IOI)<sup><a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>,<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>–<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a></sup>. Therefore, it is important to use anti-VEGF drugs appropriately according to the MNV subtype or response to first- or second-line treatments.</p>
<p id="Par10">Faricimab, a novel anti-VEGF drug, has demonstrated vision benefits and favorable anatomical outcomes in major trials and has a unique mechanism that inhibits both VEGF-A and Ang-2, which can allow an interval of injection of up to 16 weeks and stabilization of vessels<sup><a href="#CR18" class="usa-link" aria-describedby="CR18">18</a></sup>. Recently, several studies on switching to intravitreal faricimab at 6 months or 1 year have reported its efficacy in maintaining the BCVA, improving anatomical outcomes, and extending the injection interval<sup><a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>–<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup>. However, no studies have followed patients for longer than one year.</p>
<p id="Par11">The purpose of the current study was to clarify the efficacy of intravitreal injections of faricimab in patients with aflibercept-refractory nAMD over a 2-year follow-up period.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Results</h2>
<p id="Par12">Thirty-one eyes of 30 Japanese patients (22 men, 8 women; mean age ± standard deviation, 76.0 ± 7.5 years; range, 59–92 years) were included in the current study. Sixteen eyes (34%) were excluded because they were switched to brolucizumab owing to insufficient efficacy of faricimab within 24 months (Fig. <a href="#Fig1" class="usa-link">1</a>). All of the 16 eyes were switched to IVbr within 12 months after a mean of 3.4 (1–6) injections of faricimab.</p>
<figure class="fig xbox font-sm" id="Fig1"><h3 class="obj_head">Fig. 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370928_41598_2025_15194_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa78/12370928/9261f80d71f1/41598_2025_15194_Fig1_HTML.jpg" loading="lazy" id="d33e247" height="498" width="686" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flowchart summary of reviewed and examined cases in the current study. Months 24 refer to the months after initial treatment. SRF: subretinal fluid.</p></figcaption></figure><p id="Par14">All patients (31 eyes of 30 patients) were Japanese and were followed-up for at least 24 months. The proportion MNV was as follows: type 1 MNV, 21 eyes (67.7%); mixed (type 1 + Type 2) MNV, 4 eyes (12.9%); PCV, 6 eyes (19.4%) (Table <a href="#Tab1" class="usa-link">1</a>). All eyes had a treatment history of IVA, and the mean number of previous injections of aflibercept and the mean interval of IVA were 15.5(5–38) times and 10.0 (6–12) weeks, respectively. At baseline (at first intravitreal injection of faricimab: IVF), subretinal fluid (SRF) was observed in 26 eyes (83.9%), ME was observed in 7 eyes (22.6%), and PED was observed in 16 eyes (51.6%) (Table <a href="#Tab1" class="usa-link">1</a>).</p>
<section class="tw xbox font-sm" id="Tab1"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Baseline characteristics of the included patients.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Characteristic</th>
<th align="left" colspan="1" rowspan="1"></th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Patients, no.</td>
<td align="left" colspan="1" rowspan="1">30</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Women</td>
<td align="left" colspan="1" rowspan="1">8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Men</td>
<td align="left" colspan="1" rowspan="1">22</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Age (years)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mean ± SD</td>
<td align="left" colspan="1" rowspan="1">76.0 ± 7.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Eyes, no.</td>
<td align="left" colspan="1" rowspan="1">31</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">LogMAR VA (Snellens)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mean</td>
<td align="left" colspan="1" rowspan="1">0.30 (20/40)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Median</td>
<td align="left" colspan="1" rowspan="1">0.22 (20/33)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Range</td>
<td align="left" colspan="1" rowspan="1">1.00 (20/200) to 0.00 (20/20)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MNV subtype, no.</td>
<td align="left" colspan="1" rowspan="1">31</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Type 1</td>
<td align="left" colspan="1" rowspan="1">21</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Type 2</td>
<td align="left" colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mixed (type 1 + type 2)</td>
<td align="left" colspan="1" rowspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PCV</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Type 3</td>
<td align="left" colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IRF, no (%)</td>
<td align="left" colspan="1" rowspan="1">7 (22.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SRF, no (%)</td>
<td align="left" colspan="1" rowspan="1">26 (83.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PED, no (%)</td>
<td align="left" colspan="1" rowspan="1">16 (51.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Number of IVAs (before faricimab-switch)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mean</td>
<td align="left" colspan="1" rowspan="1">15.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Median</td>
<td align="left" colspan="1" rowspan="1">15.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Range</td>
<td align="left" colspan="1" rowspan="1">5 to 38</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Last IVA interval</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mean ± SD</td>
<td align="left" colspan="1" rowspan="1">10.0 ± 2.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Macular atrophy, no.</td>
<td align="left" colspan="1" rowspan="1">17</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Type 1 MNV</td>
<td align="left" colspan="1" rowspan="1">11</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mixed (type 1 + type 2) MNV</td>
<td align="left" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PCV</td>
<td align="left" colspan="1" rowspan="1">4</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p12"><p>SD, standard deviation; VA, visual acuity; MNV, macular neovascularization; PCV, polypoidal choroidal vasculopathy; ME, macular edema; IRF, intraretinal fluid; SRF, subretinal fluid; PED, pigment epithelial detachment; IVA, intravitreal injection of aflibercept.</p></div></div></section><p id="Par16">The mean logarithm of the minimum angle of resolution (logMAR) BCVA (Snellen equivalent) levels were 0.30 (20/40) at baseline, 0.24 (20/35) at 3 months after treatment (month 3), 0.23 (20/35) at month 6, 0.24 (20/35) at month 9, 0.25 (20/36) at month 12, 0.29 (20/39) at month 16, 0.29 (20/39) at month 20, and 0.30 (20/40) at month 24. A significant improvement in BCVA was observed at 3 (<em>P</em> &lt; 0.05), 6 (<em>P</em> &lt; 0.05), and 9 (<em>P</em> &lt; 0.05) months (Fig. <a href="#Fig2" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h3 class="obj_head">Fig. 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370928_41598_2025_15194_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa78/12370928/e26af2bf1b48/41598_2025_15194_Fig2_HTML.jpg" loading="lazy" id="d33e451" height="494" width="691" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Changes in the mean best-corrected visual acuity (BCVA) in eyes with neovascular age-related macular degeneration treated by switching from aflibercept 2 mg to faricimab during a 24-month follow-up period. The mean BCVA improved significantly at months 3, 6, 9. Months 3, 6, 9, 12, 16, 20 and 24 refer to the months after initial treatment. <strong><em>*</em></strong>
<em>P</em> &lt; 0.05 (paired <em>t</em>-test). logMAR, logarithm of the minimum angle of resolution.</p></figcaption></figure><p id="Par18">The mean changes in BCVA at months 1, 3, 6, 9, 12, 16, 20, and 24 were 0.61, 0.68, 0.60, 0.49, 0.17, 0.10, 0.02 lines, respectively. At 24 months, an improvement in BCVA of ≥ 3 lines was seen in 2 (6.5%) of the 12 eyes, a decrease in BCVA of ≥ 3 lines was seen in 3 (9.7%) eyes, and the remaining 26 (83.9%) eyes had stable BCVA (defined as a loss of &lt; 3 lines of vision).</p>
<p id="Par19">The mean central retinal thickness (CRT) significantly decreased from 245 ± 77 μm at baseline to 174 ± 53 μm at month 3 (<em>P</em> &lt; 0.0001), 175 ± 84 μm at month 6 (<em>P</em> &lt; 0.0001), 176 ± 60 μm at month 9 (<em>P</em> &lt; 0.0001), 168 ± 82 μm at month 12 (<em>P</em> &lt; 0.0001), 167 ± 86 μm at month 16 (<em>P</em> &lt; 0.001), 170 ± 103 μm at month 20 (<em>P</em> &lt; 0.001), and 152 ± 48 μm at month 24 (<em>P</em> &lt; 0.0001) (Fig. <a href="#Fig3" class="usa-link">3</a>). The mean subfoveal choroidal thinning (SFCT) also significantly decreased to 176 ± 71 μm at month 3 (<em>P</em> &lt; 0.01), 171 ± 67 μm at month 6 (<em>P</em> &lt; 0.001), 167 ± 63 μm at month 9 (<em>P</em> &lt; 0.001), 170 ± 67 μm at month 12 (<em>P</em> &lt; 0.001), 165 ± 68 μm at month 16 (<em>P</em> &lt; 0.0001), 162 ± 68 μm at month 20 (<em>P</em> &lt; 0.0001), and 162 ± 66 μm at month 24 (<em>P</em> &lt; 0.0001) relative to baseline (190 ± 67 μm) (Fig. <a href="#Fig4" class="usa-link">4</a>).</p>
<figure class="fig xbox font-sm" id="Fig3"><h3 class="obj_head">Fig. 3.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370928_41598_2025_15194_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa78/12370928/5954bfc66dc8/41598_2025_15194_Fig3_HTML.jpg" loading="lazy" id="d33e525" height="495" width="702" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Changes in the central retinal thickness (CRT) in eyes with neovascular age-related macular degeneration. The mean CRT significantly decreased after treatment. Months 3, 6, 9, 12, 16, 20 and 24 refer to the months after initial treatment. <strong><em>*</em></strong>
<em>P</em> &lt; 0.0001 (paired <em>t</em>-test).</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig4"><h3 class="obj_head">Fig. 4.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370928_41598_2025_15194_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa78/12370928/11128412fc97/41598_2025_15194_Fig4_HTML.jpg" loading="lazy" id="d33e557" height="468" width="702" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Changes in the subfoveal choroidal thinning (SFCT) in eyes with neovascular age-related macular degeneration. The mean CRT significantly decreased after treatment. Months 3, 6, 9, 12, 16, 20 and 24 refer to the months after initial treatment. <sup>†</sup>
<em>P</em> &lt; 0.01; <strong><em>*</em></strong>
<em>P</em> &lt; 0.001; <strong><em>**</em></strong>
<em>P</em> &lt; 0.0001 (paired <em>t</em>-test).</p></figcaption></figure><p id="Par22">At month 24, 22 eyes (70.0%) had achieved a dry macula (dry group). Of the remaining 9 eyes, 4 had SRF and 5 had macular edema (wet group). The mean logMAR BCVA at month 24 was 0.15 in the dry group and 0.66 in the wet group, which was a statistically significant difference (<em>P</em> &lt; 0.001), despite there being no difference in the mean logMAR BCVA at baseline between the dry (0.23) and wet (0.47) groups (<em>P</em> = 0.055) (Mann-Whitney U test). The mean changes in BCVA at month 24 improved by 0.80 lines in the dry group and declined by 1.53 lines in the wet group, which also amounted to a statistically significant difference (<em>P</em> &lt; 0.001, Mann-Whitney U test). The mean interval between faricimab injections in the dry and wet groups at 24 months was 9.1 weeks. PED disappeared in 5 eyes, decreased in 4 eyes, and remained in 7 eyes. Figures <a href="#Fig5" class="usa-link">5</a>, <a href="#Fig6" class="usa-link">6</a> and <a href="#Fig7" class="usa-link">7</a> show ocular images obtained from patients treated with switching to faricimab.</p>
<figure class="fig xbox font-sm" id="Fig5"><h3 class="obj_head">Fig. 5.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370928_41598_2025_15194_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa78/12370928/44f01138d289/41598_2025_15194_Fig5_HTML.jpg" loading="lazy" id="d33e609" height="728" width="778" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>An 86-year-old man with type 1 macular neovascularization (MNV). At baseline, the best-corrected visual acuity (VA) is 0.70 logarithm of the minimum angle of resolution VA (Snellen equivalent; 20/100) and 38 injections of aflibercept were administered, with the last injection of aflibercept being 4 weeks prior to the baseline evaluation. <strong>A</strong> A red-free photograph showing change in the elevation of retinal pigmented epithelium (RPE) and drusen, with the absence of hemorrhages in the macular area. Horizontal (<strong>B</strong>) and vertical (<strong>C</strong>) optical coherence tomography (OCT) images show subretinal fluid and RPE elevation due to suspected type 1 MNV. <strong>D</strong> An <em>en face</em> image of OCT angiography demonstrates an abnormal vascular mass, consistent with a diagnosis of type 1 macular neovascularization (arrows). <strong>E</strong> A short-wavelength autofluorescence image showing macular atrophy as a small area of hypoautofluorescence at the temporal side of the fovea (arrow).</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig6"><h3 class="obj_head">Fig. 6.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370928_41598_2025_15194_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa78/12370928/6a2124205e4f/41598_2025_15194_Fig6_HTML.jpg" loading="lazy" id="d33e642" height="725" width="780" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Twenty-four months in the same case described in Fig. <a href="#Fig4" class="usa-link">4</a>. After 12 faricimab injections (8-week interval of a fixed regimen at month 24), the best-corrected visual acuity (VA) improved to 0.30 logarithm of the minimum angle of resolution VA (Snellen equivalent; 20/40). <strong>A</strong> A red-free photograph showing the absence of hemorrhages and edema in the macular area. Horizontal (<strong>B</strong>) and vertical (<strong>C</strong>) optical coherence tomography (OCT) images showing resolution of the subretinal fluid, while retinal pigmented epithelium elevation remained. <strong>D</strong> An <em>en face</em> image of OCT angiography showing a remaining abnormal vascular mass due to type 1 macular neovascularization (arrows). <strong>E</strong> A short-wavelength autofluorescence image showing that there is no enlargement of macular atrophy (visualized as hypoautofluorescence).</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig7"><h3 class="obj_head">Fig. 7.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370928_41598_2025_15194_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa78/12370928/00a0b6c27ce7/41598_2025_15194_Fig7_HTML.jpg" loading="lazy" id="d33e678" height="502" width="780" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>An 83-year-old man with type 1 macular neovascularization (MNV). At baseline, the best-corrected visual acuity (BCVA) is 0.40 logarithm of the minimum angle (logMAR) of resolution VA (Snellen equivalent; 20/50) and 6 injections of aflibercept were administered, the last injection of aflibercept being 8 weeks prior to baseline. <strong>A</strong> A red-free photograph shows elevation of retinal pigmented epithelium detachment (PED) with deposits and drusen, with no hemorrhages in the macular area. Horizontal (<strong>B</strong>) and vertical (<strong>C</strong>) optical coherence tomography (OCT) images showing subretinal fluid (SRF) (arrow) and PED due to type 1 MNV. <strong>D</strong> A short-wavelength autofluorescence (SW-AF) image showing hyperautofluorescence corresponding to the deposit in the red-free photograph at the macula. <strong>E</strong> Twenty-four months later, after 9 faricimab injections (12-week interval of fixed regimen at month 24), the logMAR BCV declined to 0.82 (Snellen equivalent; 20/133). A red-free photograph showing the remaining PED but a reduction in deposits. Horizontal (<strong>F</strong>) and vertical (<strong>G</strong>) OCT images showing the persistence of PED and SRF (arrow). <strong>H</strong> An SW-AF image showing the absence of macular atrophy with hypoautofluorescence.</p></figcaption></figure><p id="Par26">During the 24-month follow-up period, the mean number of faricimab injections was 9.1 (7–12) and the mean interval was 11.8 (8–16) weeks. Eighteen eyes (58.1%) had injection intervals of ≥ 12 weeks during follow-up. The mean interval of faricimab injection at month 24 was significantly longer than the mean interval of aflibercept injection at baseline (<em>p</em> = 0.014, Mann-Whitney U test).</p>
<p id="Par27">Macular atrophy detected using short-wavelength autofluorescence (SW-AF) was observed in 17 (54.8%) eyes at baseline (type 1 MNV, 11 eyes (64.7%); mixed (type 1 + Type 2) MNV, 2eyes (11.8%); PCV, 4 eyes (23.5%)) (Table <a href="#Tab1" class="usa-link">1</a>). The mean logMAR BCVA (Snellen equivalent) levels of the 17eyes with macular atrophy and the remaining 14 eyes without macular atrophy at baseline were 0.33 (20/43) and 0.27 (20/37), respectively, with no significant difference (<em>P</em> = 0.57) (Mann-Whitney U test). At month 24, the progression of macular atrophy or newly developing macular atrophy was observed in 3 eyes (9.7%), which showed a decline of 1.0 line.</p>
<p id="Par28">There were no complications, including subretinal hemorrhage (&gt; 1 disc diameter), RPE tear, ocular inflammation, intraocular pressure &gt; 21 mmHg, severe vision loss, endophthalmitis, cataract progression, or systemic adverse events (Table <a href="#Tab2" class="usa-link">2</a>).</p>
<section class="tw xbox font-sm" id="Tab2"><h3 class="obj_head">Table 2.</h3>
<div class="caption p"><p>Complications during 24 months follow-up.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Complication</th>
<th align="left" colspan="1" rowspan="1">
<em>n</em> (%)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Severe vision loss (defined as a loss of 6 or more lines of vision using logMAR conversion)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Subretinal hemorrhage (&gt; 1 disc diameter)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">RPE tear,</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ocular inflammation</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Progression of macular atrophy</td>
<td align="left" colspan="1" rowspan="1">2 (6.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Newly developing macular atrophy</td>
<td align="left" colspan="1" rowspan="1">1 (3.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Intraocular pressure &gt; 21 mmHg</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Endophthalmitis</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cataract progression</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Systemic adverse events</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p34"><p>logMAR, logarithm of the minimum angle of resolution; RPE, retinal pigmented epithelium.</p></div></div></section></section><section id="Sec3"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par30">The current study showed that switching to intravitreal injection of faricimab stabilized VA and significantly improved anatomical changes in patients with nAMD refractory to aflibercept during the 24 months. Moreover, the achievement of a dry macula at month 24 was significantly related to the VA levels and change in VA at month 24.</p>
<p id="Par31">nAMD is responsible for significant visual loss and should be considered as an early and appropriate treatment. Anti-VEGF treatment with ranibizumab, aflibercept, and brolucizumab has become the standard therapy for nAMD in clinical settings<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>–<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a></sup>. However, caution should be taken when considering well-known problems, including the decline in BCVA and high prevalence of macular atrophy in the 7-year results with ranibizumab or IOI may develop as a complication in patients treated with brolucizumab<sup><a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>,<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>–<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a></sup>. Although it is difficult to avoid these problems or complications completely, the appropriate use of anti-VEGF drugs according to the MNV subtype or response to first- or second-line treatments could be important. Several reports on switching to IVF showed stabilization of the VA and significant efficacy in improving anatomical changes<sup><a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>–<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup>. However, most reports had a follow-up of ≤ 12 months; therefore, the 24-month outcomes were unclear. In the present study, all eyes had a history of IVA treatment, which showed inadequate efficacy with regard to anatomical changes. Therefore, we switched to IVF, and 22 eyes (70.0%) achieved a dry macula (dry group). The remaining 9 eyes showed exudation (wet group) at month 24. The dry group showed significantly better BCVA and improvement at 24 months. Therefore, achieving a dry macula may be important for improving or maintaining visual acuity (VA) in the long-term follow-up treatment of nAMD.</p>
<p id="Par32">The 7-year results with ranibizumab showed a mean 8.6-letter decrease in BCVA, and one of the main reasons was the persistence of active exudative disease using the PRN regimen<sup><a href="#CR20" class="usa-link" aria-describedby="CR20">20</a></sup>. It is important but difficult to achieve a dry macula with fewer injections. In the current study, we used a “treat and extend, then fix” regimen, which could be easier for all investigators and less stressful for patients, due to the scheduling of treatment. The mean number faricimab injections during the 24-months study period was 9.1 (7–12), and in 18 eyes (58.1%), an injection interval of ≥ 12 weeks was achieved during follow-up. The mean interval of faricimab injections at month 24 was 11.8 weeks, which was significantly longer (<em>p</em> = 0.024) than the mean interval of aflibercept injections (10 weeks) before the baseline. The CATT study reported that frequent anti-VEGF injections were associated with a higher incidence of macular atrophy, and the Vascular Endothelial Growth Factor in Age-Related Choroidal Neovascularization Trial 2-year results study also reported that continuous anti-VEGF therapy was associated with a higher incidence of atrophy<sup><a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>,<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup>. Therefore, the current study demonstrates that switching to faricimab with a “treat and extend, then fix” regimen may be useful for reducing the number of injections, and should be considered for the long-term management of patients with nAMD.</p>
<p id="Par33">PED is one of the primary indicators of the presence of MNV<sup><a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>,<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a></sup>. The regression of PED in nAMD patients after administration of anti-VEGF drugs may be strongly related to the delivery of anti-VEGF drugs to MNV under the RPE and the degree of MNV regression. Faricimab has been reported to reduce the height of PED<sup><a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>,<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a></sup>. In the current study, although the height or size of PED was not calculated, disappearance or reduction of PED was achieved in 9 eyes (56.3%) of 16 eyes that had PED at baseline. Faricimab also may be adequate effective to MNV under the RPE.</p>
<p id="Par34">In the current study, we excluded 16 of 47 eyes (34%) because patients were switched to brolucizumab after faricimab showed insufficient efficacy. All 16 eyes were switched to IVbr within 12 months of a mean of 3.4 (1–6) IVFs. Although it is difficult to precisely determine the efficacy of anti-VEGF drugs, the remaining 31 eyes included in the current study showed significant improvement in anatomical changes, and the achievement of dry macula at month 24 was significantly associated with VA levels and changes in VA at month 24. Further switching to another anti-VEGF drugs (e.g., brolucizumab) may be needed during the long-term management of nAMD.</p>
<p id="Par35">It is well known that macular atrophy is most strongly associated with the outcomes of VA during long-term follow-up<sup><a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>,<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup>. However, theoretically, it is very difficult to avoid macular atrophy. In the current study, macular atrophy was already seen in 17 (54.8%) eyes at baseline, with no significant difference in BCVA compared with the remaining 14 eyes without macular atrophy. At month 24, although the progression of macular atrophy or newly developing macular atrophy was only seen in 3 eyes (9.7%), all eyes showed a decline of VA (mean decline, 1.0 line). Progressive or new macular atrophy was highly dependent on visual outcomes. Although the current study had a small sample size and a follow-up period of only 2 years, the low incidence of macular atrophy in the current study suggests that switching to faricimab when anti-VEGF therapy is ineffective may be useful for reducing the causes of macular atrophy. The mechanism underlying the development of macular atrophy remains to be elucidated; however, most ophthalmologists would aspire to avoid this complication. Although faricimab has a novel effect on the stabilization of vessels by inhibiting Ang-2, it is difficult to demonstrate a significant effect on the stabilization of blood vessels relative to conventional anti-VEGF drugs in clinical practice. A study using bispecific Ang-2 and VEGF antibody-treated mice demonstrated a relationship with decreased collagen remodeling in vitro<sup><a href="#CR34" class="usa-link" aria-describedby="CR34">34</a></sup>. The presence of fibrosis at month 12 in patients with nAMD has been reported to be strongly associated with poor VA at month 12<sup><a href="#CR35" class="usa-link" aria-describedby="CR35">35</a></sup>. The novel characteristics of faricimab should be expected to prevent the development of fibrosis in the clinical setting, and since the incidence of macular atrophy was low in the current study, further consideration should be given to the fact that faricimab may also reduce macular atrophy in the clinical setting.</p>
<p id="Par36">During the 24-month follow-up period of the current study, none of the complications that occasionally occur after brolucizumab injection were observed after faricimab injection (e.g., unexpected severe decline in VA, RPE tear, increased subretinal hemorrhage, or IOI), and no other general complications were observed. If brolucizumab is required because faricimab is ineffective, the use of the laser flare-cell photometer (LFP) score may prove beneficial in predicting and following IOI, as we previously reported<sup><a href="#CR23" class="usa-link" aria-describedby="CR23">23</a></sup>.</p>
<p id="Par37">The present study was associated with some limitations. The current study was a single-center, retrospective, in nature with a relatively small population and a two-year follow-up period. The small sample size due to excluding 16 eyes may have led to selection bias, especially in subgroup comparisons, which may limit statistical analysis. Further large, long-term, prospective, randomized studies are needed to determine the efficacy and safety profiles of switching to intravitreal faricimab in patients with aflibercept-refractory nAMD.</p>
<p id="Par38">In conclusion, the current study demonstrated that switching to intravitreal faricimab significantly improved the anatomical changes over a 24-month period in patients with aflibercept-refractory nAMD.</p></section><section id="Sec4"><h2 class="pmc_sec_title">Methods</h2>
<p id="Par39">We retrospectively reviewed 47 consecutive eyes of 45 Japanese patients (32 men, 13 women; age range, 59–91 years; mean age 75.8 years) with nAMD who switched from aflibercept 2 mg (Eylea; Bayer) to faricimab at Iwaki City Medical Center from June to September in 2022, and who were followed for at least 2 years (Fig. <a href="#Fig1" class="usa-link">1</a>).</p>
<p id="Par40">All eyes had persistent or recurrent exudation with intraretinal or subretinal fluid or sub-RPE fluid despite treatment with the IVA on a treat-and-extend (TAE) regimen, and the treatment interval was not extended to 12 weeks after more than 6 months of follow-up. All eyes were initially treated with 3 monthly IVAs, followed by a TAE regimen. The TAE regimen using IVA was selected based on the presence of disease activity at intervals of 4–16 weeks<sup><a href="#CR36" class="usa-link" aria-describedby="CR36">36</a></sup>. All patients were switched to IVF, followed by intervals of 8–16 weeks with fixed injections at the most appropriate interval in the maintenance phase. The interval between the first and second IVF injections was selected as the last interval of the previous IVA. We decided the interval of fixed injection with “treat and extend, then fix” regimen by extending for 4 weeks or shortening by 2 weeks according to the presence of intraretinal or subretinal fluid on OCT B scans<sup><a href="#CR36" class="usa-link" aria-describedby="CR36">36</a></sup>. Eyes in which the injection of faricimab was discontinued due to inadequate efficacy were excluded from the study, and switching to brolucizumab was planned.</p>
<p id="Par41">After a detailed explanation of the potential risks and benefits, all patients provided their written informed consent for treatment (particularly for switching to faricimab) and the retrospective chart review of this study. The Institutional Review Board/Ethics Committee of Iwaki City Medical Center approved this observational study with regard to the protocol, including all methods, treatments, follow-up, and retrospective comparative analyses performed in this study. All of the study protocols adhered to the principles of the Declaration of Helsinki.</p>
<p id="Par42">All patients underwent a standardized examination, including slit-lamp biomicroscopy with a contact lens, red-free fundus photography, fluorescein angiography (FA), and/or indocyanine green angiography (ICGA) with a fundus camera (TRC-50 FA/IA/IMAGEnet H1024 system; Topcon, Tokyo, Japan), spectral-domain optical coherence tomography (SD-OCT) (RS-3000, Mirante; Nidek, Gamagori, Japan), and OCT angiography (OCTA) (RS-3000, Mirante; Nidek, Gamagori, Japan) during the follow-up period. CRT and SFCT were measured at each visit using an internal caliper software program. MNV subtype was diagnosed at first treatment with IVA based on the results of FA, ICGA, OCT and/or OCT angiography (OCTA). Patients with a dry macula at 24 months were defined as the dry group, whereas patients with SRF or macular edema were defined as the wet group.</p>
<p id="Par43">Macular atrophy was defined as the area with increased visibility of the choroidal vasculature on fundus photographs and SW-AF images with hypoautofluorescence &gt; 175 mm in the linear dimension<sup><a href="#CR37" class="usa-link" aria-describedby="CR37">37</a></sup>. We examined the SW-AF at baseline and month 24.</p>
<p id="Par44">The mean BCVA was calculated using the logarithm of the minimum angle of resolution (logMAR) scale, using BCVA measured with a Japanese standard decimal VA chart. Stable BCVA was defined as a defined as a loss of &lt; 3 lines of vision using logMAR conversion. We converted the decimal VA into Early Treatment Diabetic Retinopathy Study VA letter scores using a mathematical method to present the cases, as previously reported, according to the Japanese guidelines for ranibizumab retreatment<sup><a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>,<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a></sup>.</p>
<p id="Par45">In all eyes, the vitreous cavity was injected with faricimab 3.5 to 4.0 millimeters posterior to the corneal limbus using a 30- or 34-gauge needle under topical anesthesia applied according to the Japanese guidelines.</p>
<p id="Par46">Statistical analyses were performed using Student’s <em>t</em>-test to analyze the visual, CRT, and SFCT outcomes, and Mann-Whitney U test for comparison of the results between dry and wet groups, subgroups with and without macular atrophy, and the mean interval injections of faricimab and aflibercept. P values of &lt; 0.05 were considered to indicate statistical significance.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Conceptualization: M.S.Analysis: M.S., K.I.Writing: M.S.All authors reviewed the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Data availability</h2>
<p>The datasets provided within the manuscript and analyzed during the current study are available on reasonable request from the corresponding author.</p></section><section id="notes3"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par47">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Ferris, F. L. 3, Fine, S. L., Hyman, L. &amp; rd., &amp; Age-related macular degeneration and blindness due to neovascular maculopathy. <em>Arch. Ophthalmol.</em><strong>102</strong>, 1640–1642 (1984).
</cite> [<a href="https://doi.org/10.1001/archopht.1984.01040031330019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6208888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ferris,%20F.%20L.%203,%20Fine,%20S.%20L.,%20Hyman,%20L.%20&amp;%20rd.,%20&amp;%20Age-related%20macular%20degeneration%20and%20blindness%20due%20to%20neovascular%20maculopathy.%20Arch.%20Ophthalmol.102,%201640%E2%80%931642%20(1984)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. <em>Arch. Ophthalmol.</em><strong>109</strong>, 1220–1231 (1991).
</cite> [<a href="https://doi.org/10.1001/archopht.1991.01080090044025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1718250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Macular%20Photocoagulation%20Study%20Group.%20Laser%20photocoagulation%20of%20subfoveal%20neovascular%20lesions%20in%20age-related%20macular%20degeneration.%20Results%20of%20a%20randomized%20clinical%20trial.%20Arch.%20Ophthalmol.109,%201220%E2%80%931231%20(1991)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Gass, J. D. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. <em>Am. J. Ophthalmol.</em><strong>118</strong>, 285–298 (1994).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/7521987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gass,%20J.%20D.%20Biomicroscopic%20and%20histopathologic%20considerations%20regarding%20the%20feasibility%20of%20surgical%20excision%20of%20subfoveal%20neovascular%20membranes.%20Am.%20J.%20Ophthalmol.118,%20285%E2%80%93298%20(1994)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Yannuzzi, L. A., Sorenson, J., Spaide, R. F. &amp; Lipson, B. Idiopathic polypoidal choroidal vasculopathy (IPCV). <em>Retina</em><strong>10</strong>, 1–8 (1990).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/1693009/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yannuzzi,%20L.%20A.,%20Sorenson,%20J.,%20Spaide,%20R.%20F.%20&amp;%20Lipson,%20B.%20Idiopathic%20polypoidal%20choroidal%20vasculopathy%20(IPCV).%20Retina10,%201%E2%80%938%20(1990)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Yannuzzi, L. A. et al. Retinal angiomatous proliferation in age-related macular degeneration. <em>Retina</em><strong>21</strong>, 416–434 (2001).
</cite> [<a href="https://doi.org/10.1097/00006982-200110000-00003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11642370/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yannuzzi,%20L.%20A.%20et%20al.%20Retinal%20angiomatous%20proliferation%20in%20age-related%20macular%20degeneration.%20Retina21,%20416%E2%80%93434%20(2001)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Maruko, I., Iida, T., Saito, M., Nagayama, D. &amp; Saito, K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. <em>Am. J. Ophthalmol.</em><strong>144</strong>, 15–22 (2007).
</cite> [<a href="https://doi.org/10.1016/j.ajo.2007.03.047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17509509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maruko,%20I.,%20Iida,%20T.,%20Saito,%20M.,%20Nagayama,%20D.%20&amp;%20Saito,%20K.%20Clinical%20characteristics%20of%20exudative%20age-related%20macular%20degeneration%20in%20Japanese%20patients.%20Am.%20J.%20Ophthalmol.144,%2015%E2%80%9322%20(2007)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Spaide, R. F. et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on neovascular Age-Related macular degeneration nomenclature study group. <em>Ophthalmology</em><strong>127</strong>, 616–636 (2020).
</cite> [<a href="https://doi.org/10.1016/j.ophtha.2019.11.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11559632/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31864668/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Spaide,%20R.%20F.%20et%20al.%20Consensus%20nomenclature%20for%20reporting%20neovascular%20age-related%20macular%20degeneration%20data:%20Consensus%20on%20neovascular%20Age-Related%20macular%20degeneration%20nomenclature%20study%20group.%20Ophthalmology127,%20616%E2%80%93636%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Saito, M. et al. Long-term characteristics of exudative age-related macular degeneration in Japanese patients. <em>PLoS One</em>. <strong>16</strong>, e0261320 (2021).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0261320" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8670714/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34905560/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saito,%20M.%20et%20al.%20Long-term%20characteristics%20of%20exudative%20age-related%20macular%20degeneration%20in%20Japanese%20patients.%20PLoS%20One.%2016,%20e0261320%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Kvanta, A., Algvere, P. V., Berglin, L. &amp; Seregard, S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. <em>Invest. Ophthalmol. Vis. Sci.</em><strong>37</strong>, 1929–1934 (1996).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/8759365/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kvanta,%20A.,%20Algvere,%20P.%20V.,%20Berglin,%20L.%20&amp;%20Seregard,%20S.%20Subfoveal%20fibrovascular%20membranes%20in%20age-related%20macular%20degeneration%20express%20vascular%20endothelial%20growth%20factor.%20Invest.%20Ophthalmol.%20Vis.%20Sci.37,%201929%E2%80%931934%20(1996)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Kliffen, M., Sharma, H. S., Mooy, C. M., Kerkvliet, S. &amp; de Jong, P. T. Increased expression of angiogenic growth factors in age-related maculopathy. <em>Br. J. Ophthalmol.</em><strong>81</strong>, 154–162 (1997).
</cite> [<a href="https://doi.org/10.1136/bjo.81.2.154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1722110/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9059252/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kliffen,%20M.,%20Sharma,%20H.%20S.,%20Mooy,%20C.%20M.,%20Kerkvliet,%20S.%20&amp;%20de%20Jong,%20P.%20T.%20Increased%20expression%20of%20angiogenic%20growth%20factors%20in%20age-related%20maculopathy.%20Br.%20J.%20Ophthalmol.81,%20154%E2%80%93162%20(1997)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Oh, H. et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. <em>Invest. Ophthalmol. Vis. Sci.</em><strong>40</strong>, 1891–1898 (1999).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/10440240/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oh,%20H.%20et%20al.%20The%20potential%20angiogenic%20role%20of%20macrophages%20in%20the%20formation%20of%20choroidal%20neovascular%20membranes.%20Invest.%20Ophthalmol.%20Vis.%20Sci.40,%201891%E2%80%931898%20(1999)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Krzystolik, M. G. et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. <em>Arch. Ophthalmol.</em><strong>120</strong>, 338–346 (2002).
</cite> [<a href="https://doi.org/10.1001/archopht.120.3.338" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11879138/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Krzystolik,%20M.%20G.%20et%20al.%20Prevention%20of%20experimental%20choroidal%20neovascularization%20with%20intravitreal%20anti-vascular%20endothelial%20growth%20factor%20antibody%20fragment.%20Arch.%20Ophthalmol.120,%20338%E2%80%93346%20(2002)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group et al. Ranibizumab and bevacizumab for treatment of neovascular Age-related macular degeneration: Two-year results. <em>Ophthalmology</em><strong>119</strong>, 1388–1398 (2012).
</cite> [<a href="https://doi.org/10.1016/j.ophtha.2012.03.053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3389193/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22555112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Comparison%20of%20Age-related%20Macular%20Degeneration%20Treatments%20Trials%20(CATT)%20Research%20Group%20et%20al.%20Ranibizumab%20and%20bevacizumab%20for%20treatment%20of%20neovascular%20Age-related%20macular%20degeneration:%20Two-year%20results.%20Ophthalmology119,%201388%E2%80%931398%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. <em>N Engl. J. Med.</em><strong>355</strong>, 1419–1431 (2006).
</cite> [<a href="https://doi.org/10.1056/NEJMoa054481" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17021318/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rosenfeld,%20P.%20J.%20et%20al.%20Ranibizumab%20for%20neovascular%20age-related%20macular%20degeneration.%20N%20Engl.%20J.%20Med.355,%201419%E2%80%931431%20(2006)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. <em>N Engl. J. Med.</em><strong>355</strong>, 1432–1444 (2006).
</cite> [<a href="https://doi.org/10.1056/NEJMoa062655" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17021319/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brown,%20D.%20M.%20et%20al.%20Ranibizumab%20versus%20verteporfin%20for%20neovascular%20age-related%20macular%20degeneration.%20N%20Engl.%20J.%20Med.355,%201432%E2%80%931444%20(2006)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Heier, J. S. et al. View 1 and View 2 study groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. <em>Ophthalmology</em><strong>119</strong>, 2537–2548 (2012).
</cite> [<a href="https://doi.org/10.1016/j.ophtha.2012.09.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23084240/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Heier,%20J.%20S.%20et%20al.%20View%201%20and%20View%202%20study%20groups.%20Intravitreal%20aflibercept%20(VEGF%20trap-eye)%20in%20wet%20age-related%20macular%20degeneration.%20Ophthalmology119,%202537%E2%80%932548%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Dugel, P. U. et al. HAWK and HARRIER: Phase 3, multicenter, randomized, Double-Masked trials of brolucizumab for neovascular Age-Related macular degeneration. <em>Ophthalmology</em><strong>127</strong>, 72–84 (2020).
</cite> [<a href="https://doi.org/10.1016/j.ophtha.2019.04.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30986442/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dugel,%20P.%20U.%20et%20al.%20HAWK%20and%20HARRIER:%20Phase%203,%20multicenter,%20randomized,%20Double-Masked%20trials%20of%20brolucizumab%20for%20neovascular%20Age-Related%20macular%20degeneration.%20Ophthalmology127,%2072%E2%80%9384%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Wykoff, C. C. et al. Investigators. efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. <em>Lancet</em><strong>399</strong>, 741–755 (2022).
</cite> [<a href="https://doi.org/10.1016/S0140-6736(22)00018-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35085503/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wykoff,%20C.%20C.%20et%20al.%20Investigators.%20efficacy,%20durability,%20and%20safety%20of%20intravitreal%20faricimab%20with%20extended%20dosing%20up%20to%20every%2016%20weeks%20in%20patients%20with%20diabetic%20macular%20oedema%20(YOSEMITE%20and%20RHINE):%20two%20randomised,%20double-masked,%20phase%203%20trials.%20Lancet399,%20741%E2%80%93755%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Lanzetta, P. et al. PULSAR investigators. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. <em>Lancet</em><strong>403</strong>, 1141–1152 (2024).
</cite> [<a href="https://doi.org/10.1016/S0140-6736(24)00063-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38461841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lanzetta,%20P.%20et%20al.%20PULSAR%20investigators.%20Intravitreal%20aflibercept%208%C2%A0mg%20in%20neovascular%20age-related%20macular%20degeneration%20(PULSAR):%2048-week%20results%20from%20a%20randomised,%20double-masked,%20non-inferiority,%20phase%203%20trial.%20Lancet403,%201141%E2%80%931152%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Rofagha, S. et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). <em>Ophthalmology</em><strong>120</strong>, 2292–2299 (2013).
</cite> [<a href="https://doi.org/10.1016/j.ophtha.2013.03.046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23642856/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rofagha,%20S.%20et%20al.%20Seven-year%20outcomes%20in%20ranibizumab-treated%20patients%20in%20ANCHOR,%20MARINA,%20and%20HORIZON:%20a%20multicenter%20cohort%20study%20(SEVEN-UP).%20Ophthalmology120,%202292%E2%80%932299%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Haug, S. J. et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. <em>Am. J. Ophthalmol. Case Rep.</em><strong>18</strong>, 100680 (2020).
</cite> [<a href="https://doi.org/10.1016/j.ajoc.2020.100680" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7125319/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32258827/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Haug,%20S.%20J.%20et%20al.%20Retinal%20arterial%20occlusive%20vasculitis%20following%20intravitreal%20brolucizumab%20administration.%20Am.%20J.%20Ophthalmol.%20Case%20Rep.18,%20100680%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Baumal, C. R. et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. <em>Ophthalmology</em><strong>127</strong>, 1345–1359 (2020).
</cite> [<a href="https://doi.org/10.1016/j.ophtha.2020.04.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32344075/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Baumal,%20C.%20R.%20et%20al.%20Retinal%20vasculitis%20and%20intraocular%20inflammation%20after%20intravitreal%20injection%20of%20brolucizumab.%20Ophthalmology127,%201345%E2%80%931359%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Saito, M., Kobori, H., Nozuki, N., Kogawa, S. &amp; Kudo, A. A case of intraocular inflammation after intravitreal Brolucizumab injection monitored by laser flare-cell photometer. <em>Am. J. Ophthalmol. Case Rep.</em><strong>28</strong>, 101727 (2022).
</cite> [<a href="https://doi.org/10.1016/j.ajoc.2022.101727" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9587367/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36281264/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saito,%20M.,%20Kobori,%20H.,%20Nozuki,%20N.,%20Kogawa,%20S.%20&amp;%20Kudo,%20A.%20A%20case%20of%20intraocular%20inflammation%20after%20intravitreal%20Brolucizumab%20injection%20monitored%20by%20laser%20flare-cell%20photometer.%20Am.%20J.%20Ophthalmol.%20Case%20Rep.28,%20101727%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Hikichi, T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. <em>Jpn J. Ophthalmol.</em><strong>67</strong>, 652–656 (2023).
</cite> [<a href="https://doi.org/10.1007/s10384-023-01024-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37861941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hikichi,%20T.%20Investigation%20of%20satisfaction%20with%20short-term%20outcomes%20after%20switching%20to%20faricimab%20to%20treat%20neovascular%20age-related%20macular%20degeneration.%20Jpn%20J.%20Ophthalmol.67,%20652%E2%80%93656%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Kataoka, K. et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. <em>Graefes Arch. Clin. Exp. Ophthalmol.</em><strong>262</strong>, 43–51 (2024).
</cite> [<a href="https://doi.org/10.1007/s00417-023-06222-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37668741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kataoka,%20K.%20et%20al.%20Six-month%20outcomes%20of%20switching%20from%20aflibercept%20to%20faricimab%20in%20refractory%20cases%20of%20neovascular%20age-related%20macular%20degeneration.%20Graefes%20Arch.%20Clin.%20Exp.%20Ophthalmol.262,%2043%E2%80%9351%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Szigiato, A. et al. Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. <em>Ophthalmol. Retina</em><strong>8</strong>, 10–17 (2024).
</cite> [<a href="https://doi.org/10.1016/j.oret.2023.08.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37673396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Szigiato,%20A.%20et%20al.%20Short-term%20outcomes%20of%20faricimab%20in%20patients%20with%20neovascular%20age-related%20macular%20degeneration%20on%20prior%20anti-VEGF%20therapy.%20Ophthalmol.%20Retina8,%2010%E2%80%9317%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Raimondi, R. et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. <em>Ophthalmol. Retina</em><strong>8</strong>, 537–544 (2024).
</cite> [<a href="https://doi.org/10.1016/j.oret.2023.11.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38040055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Raimondi,%20R.%20et%20al.%20Outcomes%20of%20treatment-resistant%20neovascular%20age-related%20macular%20degeneration%20switched%20from%20aflibercept%20to%20faricimab.%20Ophthalmol.%20Retina8,%20537%E2%80%93544%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Pandit, S. A. et al. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. <em>Ophthalmol. Retina</em><strong>8</strong>, 360–366 (2024).
</cite> [<a href="https://doi.org/10.1016/j.oret.2023.10.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37913992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pandit,%20S.%20A.%20et%20al.%20Clinical%20outcomes%20of%20faricimab%20in%20patients%20with%20previously%20treated%20neovascular%20age-related%20macular%20degeneration.%20Ophthalmol.%20Retina8,%20360%E2%80%93366%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Sim, S. Y. et al. Moorfields medical retina injection service. Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. <em>Ophthalmol. Retina</em><strong>9</strong>, 22–30 (2025).
</cite> [<a href="https://doi.org/10.1016/j.oret.2024.07.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39084554/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sim,%20S.%20Y.%20et%20al.%20Moorfields%20medical%20retina%20injection%20service.%20Real-world%201-year%20outcomes%20of%20treatment-intensive%20neovascular%20age-related%20macular%20degeneration%20switched%20to%20faricimab.%20Ophthalmol.%20Retina9,%2022%E2%80%9330%20(2025)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Grunwald, J. E. et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. <em>Ophthalmology</em><strong>121</strong>, 150–161 (2014).
</cite> [<a href="https://doi.org/10.1016/j.ophtha.2013.08.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3892560/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24084496/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grunwald,%20J.%20E.%20et%20al.%20Risk%20of%20geographic%20atrophy%20in%20the%20comparison%20of%20age-related%20macular%20degeneration%20treatments%20trials.%20Ophthalmology121,%20150%E2%80%93161%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Xu, L. et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. <em>Retina</em><strong>35</strong>, 176–186 (2015).
</cite> [<a href="https://doi.org/10.1097/IAE.0000000000000374" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25387047/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu,%20L.%20et%20al.%20Geographic%20atrophy%20in%20patients%20receiving%20anti-vascular%20endothelial%20growth%20factor%20for%20neovascular%20age-related%20macular%20degeneration.%20Retina35,%20176%E2%80%93186%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Schneider, M. et al. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. <em>Graefes Arch. Clin. Exp. Ophthalmol.</em><strong>262</strong>, 2153–2162 (2024).
</cite> [<a href="https://doi.org/10.1007/s00417-024-06421-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11222265/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38416237/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schneider,%20M.%20et%20al.%20Short-term%20outcomes%20of%20treatment%20switch%20to%20faricimab%20in%20patients%20with%20aflibercept-resistant%20neovascular%20age-related%20macular%20degeneration.%20Graefes%20Arch.%20Clin.%20Exp.%20Ophthalmol.262,%202153%E2%80%932162%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Mukai, R., Honjo, J., Tanaka, K. &amp; Sekiryu, T. Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment. <em>BMC Ophthalmol.</em><strong>24</strong>, 393 (2024).
</cite> [<a href="https://doi.org/10.1186/s12886-024-03663-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11373087/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39227909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mukai,%20R.,%20Honjo,%20J.,%20Tanaka,%20K.%20&amp;%20Sekiryu,%20T.%20Exploring%20the%20comparative%20regressive%20effects%20of%20aflibercept%20and%20faricimab%20on%20pigment%20epithelial%20detachment.%20BMC%20Ophthalmol.24,%20393%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Linder, M., Bennink, L., Foxton, R. H., Kirkness, M. &amp; Westenskow, P. D. In vivo monitoring of active subretinal fibrosis in mice using collagen hybridizing peptides. <em>Lab. Anim. (NY)</em>. <strong>53</strong>, 196–204 (2024).
</cite> [<a href="https://doi.org/10.1038/s41684-024-01408-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11291276/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39060633/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Linder,%20M.,%20Bennink,%20L.,%20Foxton,%20R.%20H.,%20Kirkness,%20M.%20&amp;%20Westenskow,%20P.%20D.%20In%20vivo%20monitoring%20of%20active%20subretinal%20fibrosis%20in%20mice%20using%20collagen%20hybridizing%20peptides.%20Lab.%20Anim.%20(NY).%2053,%20196%E2%80%93204%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Cheung, C. M. G. et al. The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration. <em>Ophthalmol. Retina</em><strong>3</strong>, 1045–1055 (2019).
</cite> [<a href="https://doi.org/10.1016/j.oret.2019.06.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31444144/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cheung,%20C.%20M.%20G.%20et%20al.%20The%20evolution%20of%20fibrosis%20and%20atrophy%20and%20their%20relationship%20with%20visual%20outcomes%20in%20Asian%20persons%20with%20neovascular%20age-related%20macular%20degeneration.%20Ophthalmol.%20Retina3,%201045%E2%80%931055%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Ohji, M. et al. ALTAIR investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-Week findings from ALTAIR: A randomized controlled trial. <em>Adv. Ther.</em><strong>37</strong>, 1173–1187 (2020).
</cite> [<a href="https://doi.org/10.1007/s12325-020-01236-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7089719/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32016788/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ohji,%20M.%20et%20al.%20ALTAIR%20investigators.%20Efficacy%20and%20safety%20of%20intravitreal%20aflibercept%20treat-and-extend%20regimens%20in%20exudative%20age-related%20macular%20degeneration:%2052-%20and%2096-Week%20findings%20from%20ALTAIR:%20A%20randomized%20controlled%20trial.%20Adv.%20Ther.37,%201173%E2%80%931187%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Saito, M., Itagaki, K. &amp; Sekiryu, T. Fundus autofluorescence of retinal angiomatous proliferation. <em>PLoS One</em>. <strong>15</strong>, e0243458 (2020).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0243458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7725377/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33296421/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saito,%20M.,%20Itagaki,%20K.%20&amp;%20Sekiryu,%20T.%20Fundus%20autofluorescence%20of%20retinal%20angiomatous%20proliferation.%20PLoS%20One.%2015,%20e0243458%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Tano, Y. et al. Re-treatment guideline of ranibizumab (genetical recombination) in the maintenance phase. <em>Nippon Ganka Gakkai Zasshi</em><strong>113</strong>, 1098–1103 (2009) (<strong>In Japanese</strong>).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/19994589/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tano,%20Y.%20et%20al.%20Re-treatment%20guideline%20of%20ranibizumab%20(genetical%20recombination)%20in%20the%20maintenance%20phase.%20Nippon%20Ganka%20Gakkai%20Zasshi113,%201098%E2%80%931103%20(2009)%20(In%20Japanese)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Saito, M., Iida, T. &amp; Kano, M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. <em>Retina</em><strong>32</strong>, 1250–1259 (2012).
</cite> [<a href="https://doi.org/10.1097/IAE.0b013e318236e503" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22446886/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saito,%20M.,%20Iida,%20T.%20&amp;%20Kano,%20M.%20Intravitreal%20ranibizumab%20for%20exudative%20age-related%20macular%20degeneration%20with%20good%20baseline%20visual%20acuity.%20Retina32,%201250%E2%80%931259%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The datasets provided within the manuscript and analyzed during the current study are available on reasonable request from the corresponding author.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Scientific Reports are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41598-025-15194-3"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41598_2025_Article_15194.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.3 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12370928/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12370928/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12370928%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370928/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12370928/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12370928/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40841412/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12370928/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40841412/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12370928/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12370928/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="dyQQq3zVLmFeJ4m2oPiOhSoDUGN0dELkCiKSQaOk6RTrBOryo5hqQaaaPnJoLAYN">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
